Society for Immunotherapy of Cancer (SITC) Recognizes Immunovaccine Researchers with Journal for ImmunoTherapy of Cancer (JI...
13 November 2017 - 11:05PM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced that the Society for
Immunotherapy of Cancer (SITC) has recognized Immunovaccine
researchers with the 2017 Journal for ImmunoTherapy of Cancer
(JITC) ‘Best Basic Science Paper Award.’ The company also announced
that separate research was presented via poster at the 32nd
SITC Annual Meeting.
A committee of SITC leadership and the JITC Editorial Board
reviewed Immunovaccine’s scientific paper, which is entitled
“Anti-PD-1 increases the clonality and activity of tumor
infiltrating antigen specific T cells induced by a potent immune
therapy consisting of vaccine and metronomic cyclophosphamide.” The
review committee selected the Immunovaccine paper for recognition
based on its ‘demonstration of innovative research in medical
sciences that has a direct relevance to future research in clinical
medicine.’ Immunovaccine representatives received the award at
SITC’s 32nd Annual Meeting Awards Ceremony on November 11 at the
Gaylord National Hotel & Convention Center in National Harbor,
MD.
“It’s an honor for our team of researchers to be recognized with
this prestigious SITC award. It highlights the quality of their
scientific acumen and dedication to uncovering novel ways to
leverage human immunity to fight serious diseases, including
cancer,” said Marianne Stanford, PhD, Immunovaccine’s Vice
President, Research. “I believe that this award also helps to
validate our clinical strategy and underscores the promise of our
DepoVax™-based formulations and the role they play in the treatment
landscape, particularly in combination with other advanced
immuno-modulating monotherapies, including checkpoint
inhibitors.”
The Immunovaccine poster presented at the SITC Annual Meeting is
titled “Predicting the efficacy of combination immunotherapy in a
microenvironment immune cell profiling.” The study explored using
data on the types of immune cells found within the tumor
microenvironment as a means of predicting the potential efficacy of
combination immunotherapies in tumor models. Researchers focused on
combinations based on T cell-activating agents formulated with the
Company’s proprietary DepoVax-related technology. These agents
facilitated T cell infiltration into the tumors, which is essential
for controlling tumor growth, that could be augmented by other
novel immunotherapies, such as checkpoint inhibitors.
About DepoVax DepoVax is
Immunovaccine’s proprietary delivery formulation that uses a novel
process to present stimulants to the human immune system, and
sustain them over time. The technology underlying DepoVax
formulations suspends vaccine components in a 100% oil-based
diluent that prevents their release at the site of injection. This
process forces immune cells to take up these components in an
active process, delivering them directly to immune organs such as
the lymph nodes. DepoVax formulations have undergone extensive
testing in more than 60 preclinical and seven clinical studies. In
clinical trials, these formulations have consistently demonstrated
the ability to generate robust T and B cell responses, and durable
immune responses.
About ImmunovaccineImmunovaccine Inc. is a
clinical stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious
diseases. Immunovaccine develops T cell-activating cancer
immunotherapies and other vaccine candidates based on DepoVax, the
Company’s patented platform that provides controlled and prolonged
exposure of antigens and adjuvant to the immune system.
Immunovaccine has advanced two T cell-activating therapies for
cancer through Phase 1 human clinical trials and is currently
conducting a Phase 1b study with Incyte Corporation assessing lead
cancer therapy, DPX-Survivac, as a combination therapy in ovarian
cancer. The Company is also exploring additional applications of
DepoVax, including DPX-RSV, an innovative vaccine candidate for
respiratory syncytial virus (RSV), which has recently completed a
Phase 1 clinical trial. Immunovaccine also has ongoing clinical
projects to assess the potential of DepoVax to address malaria and
the Zika virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking StatementsThis
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819 E:
info@imvaccine.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024